Previous 10 | Next 10 |
2024-05-01 16:24:49 ET More on Emergent Biosolutions New CEO Appointment A Clear Positive For Emergent BioSolutions Emergent Biosolutions Q1 2024 Earnings Preview Emergent BioSolutions receives NAI status for Baltimore Bayview manufacturing facility Read th...
Proactive changes aim to ensure long-term sustainability and growth, optimize operations, streamline processes, and allocate resources more efficiently Reorganization will align with evolving business goals, strategic priorities and new operational plan Overall efforts expected to deliver...
Nearly 9 in 10 Americans surveyed agree opioid overdoses are a concern for teenagers and college students; parents in the survey want life-saving treatment to be easily accessible in case of an emergency GAITHERSBURG, Md., May 01, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYS...
Enact Holdings Inc. (ACT) is expected to report $0.99 for Q1 2024 FormFactor Inc. (FORM) is expected to report $0.09 for Q1 2024 SAAB AB - Class B (SAABF) is expected to report for quarter end 2024-03-31 Lumos Pharma Inc. (LUMO) is expected to report $-1.21 for Q1 2024 Axis Capita...
GAITHERSBURG, Md., April 30, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced that it has entered into a “Consent, Waiver and Seventh Amendment” to its existing credit facility. “In light of this amendment, Emergent now has an extended runw...
2024-04-30 17:20:18 ET More on Emergent Biosolutions Emergent BioSolutions Inc. (EBS) Q4 2023 Earnings Call Transcript Emergent BioSolutions Inc. 2023 Q4 - Results - Earnings Call Presentation New CEO Appointment A Clear Positive For Emergent BioSolutions Eme...
2024-04-24 11:01:15 ET More on Amneal Pharmaceuticals Amneal Pharmaceuticals, Inc. (AMRX) Q4 2023 Earnings Call Transcript Amneal Pharmaceuticals, Inc. 2023 Q4 - Results - Earnings Call Presentation Bausch Health sues Amneal Pharma over Xifaxan generic Amneal...
GAITHERSBURG, Md., April 22, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, May 1, 2024, at 5:00 pm eastern time to discuss the financial results for the first quarter 2024, key business updates, revenue guidance for the second quarter of...
WARREN, N.J., April 01, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technolo...
As the first-ever U.S. Food and Drug Administration (FDA) approved over-the-counter (OTC) naloxone in 2023, Emergent is working to expand access with NARCAN ® Nasal Spray and build on its longstanding efforts with public interest entities across the country Hundreds of thousands...
News, Short Squeeze, Breakout and More Instantly...
Emergent Biosolutions Inc. Company Name:
EBS Stock Symbol:
NYSE Market:
Emergent Biosolutions Inc. Website:
New video and radio segments raise awareness of a potentially life-saving, three-step method that anyone can use to respond in a suspected opioid poisoning GAITHERSBURG, Md., July 24, 2024 (GLOBE NEWSWIRE) -- Today, Emergent BioSolutions Inc. (NYSE: EBS) announced the launch of a new opio...
GAITHERSBURG, Md., July 23, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Tuesday, August 6, 2024, at 5:00 pm eastern time to discuss the financial results for the second quarter 2024, key business updates, revenue guidance for the third quarter of...
The extension to a four-year shelf-life helps improve naloxone access as communities continue to grapple with the growing opioid epidemic; product with the extended shelf life has officially begun shipping WINNIPEG, Manitoba, July 22, 2024 (GLOBE NEWSWIRE) -- Today, Emergent BioSolution...